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hypoglycemia events (ICD-9-CM 250.8×, 251.0×, 251.1×, 251.2×) were identiﬁ ed. 
Annual total, medical, pharmacy, and diabetes-related costs for patients with or 
without the diagnosis of hypoglycemia were compared during the 12-month post-
index period. Diabetes-related medical costs included all non-pharmacy costs associ-
ated with T2DM diagnosis. Generalized linear regressions with robust standard error 
accounting for skewed cost distribution were performed, adjusting for demographics, 
comorbidities, and OADs. RESULTS: A total of 212,061 T2DM patients with at least 
one OAD treatment were identiﬁ ed. Among them, 4860 (2.29%) had a hypoglycemia 
diagnosis during the ﬁ rst year following the index date. Patients with hypoglycemia 
had signiﬁ cantly higher average annual total costs ($18,273 vs. $8908, P < 0.001) and 
diabetes-related total costs ($8969 vs. $3220, P < 0.001) than those without hypogly-
cemia. After adjusting for confounding factors, hypoglycemia patients had signiﬁ -
cantly higher incremental annual total costs and diabetes-related total costs than 
patients without hypoglycemia ($5031 and $3751, respectively, both P < 0.001). 
Similar trends were observed for annual medical costs and diabetes-related medical 
costs ($4967 and $3796, respectively, both P < 0.001). CONCLUSIONS: Hypogly-
cemia in type 2 diabetes patients initiated with OADs in a large US managed care 
setting is associated with signiﬁ cantly higher total, medical, and diabetes-related costs 
compared with those who did not experience hypoglycemia. 
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OBJECTIVES: This study was to examine the prevalence and economic burden of in 
patients with diabetes and/or related complications from Tingyi hospital in Wuhan 
China. METHODS: This was a retrospective analysis focused on hospitalization costs 
and complications for all patients diagnosed with diabetes and administered in Wuhan 
Tingyi hospital in China from June 2007 to December 2007. All information of patient 
demographic characters, clinical and costs were collected for the analysis. The descrip-
tive statistics was used to describe patients’ demographic characters, duration of the 
diseases and treatment costs. RESULTS: There were total of 295 inpatients were 
included in the study. The mean age of patients was 51.6 ± 16.0 years (range 11–87 
years), 53.56% were male. The diabetes durations (±SD) were 5.75 ± 6.04 years. 
13.56% were type 1 diabetes, and 86.44% were type 2 diabetes. The mean hospital 
stay (±SD) were 11.99 days (±0.54), and mean of hospitalization costs (±SD) were 
USD 876.6 (±39.4) (1US$ = 7.6 RMB). The patients with no complication, micro 
vascular complications, macro vascular complications or both were 10.20%, 30.27%, 
8.16%, and 51.36% respectively. Peripheral neuropathy (69.2%) and hyperlipidemia 
(64.1%) were of the highest prevalence among all the complications, and diabetic foot 
ulcer was the expensive complication with the highest treatment costs (USD657). The 
costs of tests and medications accounted for 27% and 26% of total hospitalization 
expenses. Anti–diabetes drugs, complication treatments and other drugs were of 
37.7%, 52.8%, and 9.4% respectively in the medication costs. CONCLUSIONS: 
Most of hospitalized patients had diabetes complications. Diabetic complications 
contributed to a substantial economic burden for the patients and society. It implied 
the urgent need for health-care policymakers to address this issue by adopting effective 
measures toward prevention and control of diabetes and its complications. 
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BACKGROUND: Growth hormone replacement therapy (GHRT) is an expensive 
health service excluded from the universal coverage (UC) beneﬁ t package of Thailand. 
Its high costs and exclusion from the UC beneﬁ t package prevent poor patients from 
access to such health care. OBJECTIVES: This study aims to estimate costs of provid-
ing GHRT to patients diagnosed with growth hormone deﬁ ciency (GHD). It also 
explores demand for, and supply of, and total costs per unit of height increase from 
universal access to GHRT. METHODS: Methods include comprehensive literature 
review, in-depth interviews of childhood endocrinologists from three university hos-
pitals about costs of GHRT and its current practice, and modeling costs for height 
increase using different products. RESULTS: Research ﬁ ndings indicate the incidence 
of GHD in Thailand is approximately 1 to 50,000 of people aged less than 15 years. 
A weekly dosage of GHRT recommended by the Thai Pediatric Endocrine Society 
range from 0.1 to 0.3 mg per kg depending on patient’s responses. Cessation criteria 
of GHRT comprise 1) attainment of adult height at 165 and 155 cm in male and 
female, respectively; 2) bone age above 16 and 14 years in male and female respec-
tively; and 3) the annual increase of height lower than 2.5 cm. On supply side, 
approximately 40 pediatric endocrinologists are available in public and private settings 
across the country. Costs of GHRT are varied from factors including patient’s age 
and gender, type and dose of GH use. Data from a university hospital show costs of 
GHRT range from $950 to $2580 per every 1 cm of height increase when using a 
cheaper GH product. The costs will increase from $1460 to $4000 per every 1 cm of 
height increase when using the original GH. CONCLUSIONS: High cost burden of 
GHRT poses a challenging question on whether it should be included in the UC beneﬁ t 
package. 
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OBJECTIVES: To evaluate the long-term health outcomes and economic consequences 
of the treatment of Insulin Detemir (IDet) in type 2 diabetes patients switching from 
insulin Glargine (IGla) in the setting of Chinese urban hospitals. METHODS: A 
published and validated computer simulation model of diabetes (the CORE Diabetes 
Model) was used to make the long- term (30 years) projection of health economic 
outcomes. The patient demographic information and clinical endpoints were derived 
from the PREDICTIVE subgroup study. The study was a large, multi-center, 6 months 
observational study assessing the safety and efﬁ cacy of IDet in everyday clinical 
practice. HbA1c was reduced of −0.59% by switching from IGla to IDet. Baseline risk 
factors and racial characteristic data were obtained from Chinese cohort studies. The 
market retail prices of medications were calculated to estimate treatment costs. The 
diabetes management and complications costs were obtained from Chinese published 
data and adjusted to 2009 values using the Chinese Consumer Price Index. An annual 
discounting rate of 3% was used for both health and cost outcomes. One-way sensi-
tivities analysis was performed and illustrated that the results were robust. RESULTS: 
The treatment of IDet converted from IGla was projected to reduce the cumulative 
incidences of Eye disease, Renal disease, Ulcer, Cardiovascular disease, Cataract, End-
Stage Renal Disease, Ulcer, Neuropathy, Myocardial Infarction events were reduced 
0.293%, 0.151%, 0.794%, 3.293%, 1.225% respectively. Patients’ time alive and 
free of complication was improved 0.15 year. Patient life expectancy was increased 
by 0.09 year and 0.36 quality adjusted life-year (QALY) when converting to IDet. 
The costs of complications were reduced by 4931 CNY (89,628 vs. 94,559), resulting 
in a total direct medical cost saving of 684 CNY. CONCLUSIONS: The treatment of 
IDet improved patient health and economic outcomes, and was a cost-saving treatment 
approach in a Chinese setting. 
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OBJECTIVES: To estimate the long term clinical and cost outcomes of continuous 
subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) 
of insulin in adult type 1 diabetes mellitus (T1DM) patients from a third party payer 
perspective in China. METHODS: A previously validated computer simulation model 
of diabetes (CORE Diabetes Model) was used to estimate the long-term clinical and 
cost consequences of CSII to MDI in the Chinese consumer-use setting and to calculate 
the incremental cost-effectiveness ratio (ICER). Clinical and cost data as well as treat-
ment effects and patient characteristics were obtained from previously published 
studies. Costs and clinical projections were made over patient lifetimes from a third-
party payer perspective and discounted at 3% annually. The primary input variable 
was change in HbA1c and was assumed to be an improvement of −1.2% for CSII 
compared with MDI. RESULTS: CSII was associated with improvements of 1.037 in 
quality adjusted life-years (QALYs) gained and 0.963 life-years gained per patient 
versus MDI. CSII was associated with an incremental cost-effectiveness ratio (ICER) 
of CNY 214,988 per QALY gained for CSII versus MDI. Improved glycemic control 
from CSII led to a lower incidence of lifetime diabetes complications; with the most 
signiﬁ cant reductions in proliferative diabetic retinopathy (PDR; a 29% reduction), 
end stage renal disease (ESRD; a 22% reduction) and peripheral vascular disease 
(PVD; a 15% reduction). CSII was associated with increased direct lifetime medical 
costs of Chinese Yuan (CNY) 222,994 per patient compared to MDI. CONCLU-
SIONS: For type 1 diabetes patients in China, CSII (consumer-use) would be consid-
ered cost-effective assuming a willingness-to-pay threshold of CNY 235,000 per 
QALY gained. 
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OBJECTIVES: The LEAP is a multidisciplinary management program (including 
angioplasty, bypass surgery and medical treatment) designed to enhance limb salvage 
for patients with diabetes and critical limb ischemia (CLI). This study aims to deter-
mine the cost-effectiveness of the LEAP strategy compared with the pre-LEAP strategy 
(standard practice) for treating patients with diabetes and CLI. METHODS: Clinical 
data relating to 277 patients in the LEAP were collected from 2001 until 2005. 
Comparative data were retrospectively collected for 144 patients with diabetes and 
CLI referred to the hospital in 2000. A lack of follow-up data in the pre-LEAP group 
restricted this study to the inpatient period. Signiﬁ cance of differences in therapeutic 
